Apremilast (Otezla) approved by FDA

Apremilast Compound

Apremilast (Otezla®) received FDA approval on March 21, 2014 for the treatment of adults with active psoriatic arthritis (PsA). It is the first oral medication in the U.S. with an approved indication for the treatment of PsA. The recommended dose is 30 mg BID

Current Saline Shortage

Saline Shortage

The current nationwide saline shortage has the potential to negatively impact rheumatology patients dependent on infusible products to manage their disease. Bags of normal saline (0.9%) in the 250ml-1000ml volumes are especially low.

OTREXUP™ (methotrexate) injection approved by the FDA

Methotrexate Injection Approved by FDA

OTREXUP™ (methotrexate) injection was recently approved by the U.S. Food and Drug Administration.

It is indicated for adults with severe, active rheumatoid arthritis, or children with active polyarticular juvenile idiopathic arthritis who have failed first line therapies. It is also indicated for severe, recalcitrant, disabling psoriasis.